| Name | Title | Contact Details |
|---|
We are a community bank focused on doing whats best for our customers -- whether its providing a new service that works for more people, or taking the time to ask what more we can do to help. We offer every convenience for banking off-site or on-line, but never, ever compromise on personal attention. And proud as we are of our history dating back to 1868, our sights are firmly -- and optimistically -- set on whats ahead. Gorham Savings Bank is dedicated to improving the economic and social well-being of our customers and the communities we serve and committed to be the leading financial service provider in creating economic growth, prosperity, and financial security for the citizens and communities of Southern Maine by: • Developing and delivering quality products and services to our customers. • Establishing a workplace environment that attracts and retains highly motivated, high performing employees. • Achieving sound financial results which will allow us to reinvest in our company and in our communities in a meaningful and sustainable manner. Member FDIC - Equal Housing Lender
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
GrayMatter is an industrial technology company based near Pittsburgh, Pennsylvania, with regional offices in the U.S., Canada, and India. The company specializes in digital transformation and industrial automation solutions, serving major organizations in manufacturing, energy, food and beverage, pharmaceuticals, and utilities worldwide. GrayMatter offers a variety of services aimed at improving operational efficiency and digital capabilities. Their key offerings include advanced industrial analytics, which helps companies utilize data for better decision-making, and a brilliant operations strategy that supports digital transformation initiatives. They also focus on risk mitigation during the digital transformation process. GrayMatters family of brands includes E-Merge, HTSE, Automation & Control Concepts, and Phantom Technical Services, each providing specialized automation solutions across different industries. The company has grown through strategic mergers and acquisitions, enhancing its capabilities and expanding its client base. Notable clients include major companies like Nestlé Purina PetCare and Anheuser-Busch, showcasing GrayMatters strong presence in the industrial sector.